ArticleFrontiers in immunology2026
Tumor immune microenvironment states inferred from TLS-associated immune-cell composition stratify prognosis in hepatocellular carcinoma.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structures (TLS) are ectopic immune hubs in the tumor immune microenvironment (TIME) associated with prognosis and immunotherapy response, yet commonly used TLS structural descriptors show inconsistent associations with prognosis in hepatocellular carcinoma (HCC). Here, we propose a TLS-associated immune-cell composition framework that quantifies the TIME state and predicts patient outcomes. Methods: By integrating an HCC single-cell atlas with literature-curated TLS gene sets, we defined six TLS-associated immune components (TLS6). Using TLS6 as a reference, we applied BayesPrism deconvolution to infer the relative abundance of TLS6 from bulk tumor transcriptomes. Given the divergent prognostic associations across TLS6 fractions, we applied LASSO-Cox regression to derive a two-feature TLS RiskScore retaining regulatory T cells and cDC2 cells. Results: The TLS RiskScore stratified overall survival in TCGA-LIHC and ICGC LIRI-JP and was associated with response to PD-1 blockade in an independent anti-PD-1-treated HCC cohort. In multicenter FFPE tissues, a multiplex immunofluorescence (mIF) implementation quantifying TLS-localized CD4 Conclusions: Collectively, these results support a compact, translatable TLS-associated immune-cell composition framework that provides a computable TIME-state measure associated with prognosis and response to PD-1 blockade in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.